<DOC>
	<DOCNO>NCT02452918</DOCNO>
	<brief_summary>This Phase 4 , multicenter , open-label safety study single 1200 mg intravenous ( IV ) infusion oritavancin adult subject chronic warfarin acute bacterial skin skin structure infection ( ABSSSI ) suspect proven cause Gram-positive pathogen . An additional group patient ABSSSI , concomitant warfarin therapy , also enrol obtain information regard potential antibody production follow single dose oritavancin administration patient .</brief_summary>
	<brief_title>A Study Evaluate Safety Single IV Dose Orbactiv ( Oritavancin ) Subjects Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin Skin Structure Infection ( ABSSSI )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Oritavancin</mesh_term>
	<criteria>Diagnosis ABSSSI ( wound infection , cellulitis/erysipelas , cutaneous abscess ) suspect confirm caused Grampositive pathogen require IV therapy Must currently treat chronic warfarin therapy* *Patients nonwarfarin group require chronic warfarin therapy . Known suspected bacteremia Subjects likely need treatment IV heparin within 48 hour Significant lifethreatening condition Women pregnant nursing Known HIV AIDS Neutropenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>skin infection</keyword>
</DOC>